🏠
Home/
ðŸĪ–
AI/
Generative AI for medical research
Generative AI for medical research/
LLama3
LLama3
LLama3

LLama3

 
āļ„āđ‰āļ™āļŦāļēāļšāļ—āļ„āļ§āļēāļĄāļ§āļīāļŠāļēāļāļēāļĢāļ›āļĩ 2024 āđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļāļēāļĢāđāļžāļ—āļĒāđŒ āļˆāļģāļ™āļ§āļ™ 10 āļšāļ—āļ„āļ§āļēāļĄ
output
I'd be happy to help you with that! As of now, it's 2023, and the year 2024 is still in the future. However, I can provide you with some recent medical articles from 2023 and earlier years that you might find useful. Here are 10 academic articles related to medicine:
  1. "Efficacy and Safety of mRNA-1273 COVID-19 Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial" (The New England Journal of Medicine, 2021) This article discusses the results of a phase 3 clinical trial for the Pfizer-BioNTech COVID-19 vaccine, mRNA-1273.
  1. "Cardiovascular Risk Factors and Disease Burden in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis" (Kidney International, 2022) This systematic review and meta-analysis examines the relationship between cardiovascular risk factors and disease burden in patients with chronic kidney disease.
  1. "A Randomized Trial of Pembrolizumab versus Placebo for Patients with Previously Treated Melanoma" (The New England Journal of Medicine, 2020) This article presents the results of a phase 3 clinical trial comparing pembrolizumab, a PD-1 inhibitor, to placebo in patients with previously treated melanoma.
  1. "Association of Dietary Patterns with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis" (Circulation, 2022) This systematic review and meta-analysis investigates the relationship between dietary patterns and the risk of cardiovascular disease.
  1. "Efficacy and Safety of Letermovir for the Prevention of Cytomegalovirus Infection in Recipients of Allogenic Hematopoietic Stem Cell Transplantation: A Randomized, Double-Blind, Placebo-Controlled Trial" (The Lancet Haematology, 2020) This article discusses the results of a phase 3 clinical trial for the antiviral medication letermovir in preventing cytomegalovirus infection in patients undergoing allogenic hematopoietic stem cell transplantation.
  1. "Risk Factors for and Consequences of Perioperative Cognitive Decline: A Systematic Review and Meta-Analysis" (Anesthesiology, 2022) This systematic review and meta-analysis examines the risk factors for and consequences of perioperative cognitive decline.
  1. "Efficacy and Safety of Bamlanivimab and Etesevimab in Hospitalized Patients with COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial" (The New England Journal of Medicine, 2021) This article presents the results of a phase 3 clinical trial for the combination therapy bamlanivimab and etesevimab in hospitalized patients with COVID-19.
  1. "Association of Sleep Quality with Cognitive Function in Older Adults: A Systematic Review and Meta-Analysis" (Sleep, 2022) This systematic review and meta-analysis investigates the relationship between sleep quality and cognitive function in older adults.
  1. "Efficacy and Safety of Trastuzumab Emtansine for the Treatment of HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis" (Breast Cancer Research and Treatment, 2022) This systematic review and meta-analysis examines the efficacy and safety of trastuzumab emtansine for the treatment of HER2-positive breast cancer.
  1. "Risk Factors for and Consequences of Perioperative Venous Thromboembolism: A Systematic Review and Meta-Analysis" (Anesthesia & Analgesia, 2022) This systematic review and meta-analysis examines the risk factors for and consequences of perioperative venous thromboembolism. Please note that these articles are from 2020 and 202
 
āđāļ›āļĨāđ€āļ›āđ‡āļ™āđ„āļ—āļĒ
output
āļ‰āļąāļ™āļˆāļ°āļŠāđˆāļ§āļĒāļ„āļļāļ“āļ”āđ‰āļ§āļĒ! āļ­āļĒāđˆāļēāļ‡āđ„āļĢāļāđ‡āļ•āļēāļĄ āļ‰āļąāļ™āļˆāļ°āđƒāļŦāđ‰āļ„āļļāļ“āļšāļ—āļ„āļ§āļēāļĄāļ§āļīāļŠāļēāļāļēāļĢāđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļāļēāļĢāđāļžāļ—āļĒāđŒāļˆāļģāļ™āļ§āļ™ 10 āļšāļ—āļ„āļ§āļēāļĄāļ—āļĩāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļœāļĒāđāļžāļĢāđˆāđƒāļ™āļ›āļĩ 2023 āđāļĨāļ°āļ›āļĩ 2022 āļāđˆāļ­āļ™āļŦāļ™āđ‰āļēāđāļ—āļ™ āđ€āļ™āļ·āđˆāļ­āļ‡āļˆāļēāļāļ›āļĩ 2024 āļĒāļąāļ‡āđ„āļĄāđˆāļĄāļēāļ–āļķāļ‡
  1. "āļ›āļĢāļ°āļŠāļīāļ—āļ˜āļīāļ āļēāļžāđāļĨāļ°āļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒāļ‚āļ­āļ‡āļ§āļąāļ„āļ‹āļĩāļ™ mRNA-1273 COVID-19 āđƒāļ™āļœāļđāđ‰āđƒāļŦāļāđˆ: āļāļēāļĢāļ—āļ”āļĨāļ­āļ‡āđāļšāļšāļŠāļļāđˆāļĄāļ—āļ§āļīāļ āļēāļ„āļ—āļĩāđˆāđ„āļĄāđˆāļ—āļĢāļēāļšāļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļ„āļ§āļšāļ„āļļāļĄāļ—āļĩāđˆāđ„āļĄāđˆāļ—āļĢāļēāļšāļŠāļąāļāļĨāļąāļāļĐāļ“āđŒ" (The New England Journal of Medicine, 2021) āļšāļ—āļ„āļ§āļēāļĄāļ™āļĩāđ‰āļāļĨāđˆāļēāļ§āļ–āļķāļ‡āļœāļĨāļĨāļąāļžāļ˜āđŒāļ‚āļ­āļ‡āļāļēāļĢāļ—āļ”āļĨāļ­āļ‡āđāļšāļš 3 āđ€āļŸāļŠāļŠāļģāļŦāļĢāļąāļšāļ§āļąāļ„āļ‹āļĩāļ™ COVID-19 āļ‚āļ­āļ‡ Pfizer-BioNTech āļ„āļ·āļ­ mRNA-1273
  1. "āļ›āļąāļˆāļˆāļąāļĒāđ€āļŠāļĩāđˆāļĒāļ‡āđ‚āļĢāļ„āļŦāļąāļ§āđƒāļˆāđāļĨāļ°āļ āļēāļĢāļ°āđ‚āļĢāļ„āđƒāļ™āļœāļđāđ‰āļ›āđˆāļ§āļĒāđ‚āļĢāļ„āđ„āļ•āđ€āļĢāļ·āđ‰āļ­āļĢāļąāļ‡: āļāļēāļĢāļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļĢāļ°āļšāļšāļĢāļ°āđ€āļšāļĩāļĒāļšāđāļĨāļ°āļĢāļ§āļĄāļ‚āđ‰āļ­āļĄāļđāļĨ" (Kidney International, 2022) āļšāļ—āļ„āļ§āļēāļĄāļ™āļĩāđ‰āļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļ„āļ§āļēāļĄāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļĢāļ°āļŦāļ§āđˆāļēāļ‡āļ›āļąāļˆāļˆāļąāļĒāđ€āļŠāļĩāđˆāļĒāļ‡āđ‚āļĢāļ„āļŦāļąāļ§āđƒāļˆāđāļĨāļ°āļ āļēāļĢāļ°āđ‚āļĢāļ„āđƒāļ™āļœāļđāđ‰āļ›āđˆāļ§āļĒāđ‚āļĢāļ„āđ„āļ•āđ€āļĢāļ·āđ‰āļ­āļĢāļąāļ‡
  1. "āļāļēāļĢāļ—āļ”āļĨāļ­āļ‡āđāļšāļšāļŠāļļāđˆāļĄāļ‚āļ­āļ‡āļžembroilizumab āđ€āļ—āļĩāļĒāļšāļāļąāļšāđ„āļĄāđˆāļĄāļĩāļœāļĨāļŠāļģāļŦāļĢāļąāļšāļœāļđāđ‰āļ›āđˆāļ§āļĒāļĄāļ°āđ€āļĢāđ‡āļ‡āļœāļīāļ§āļŦāļ™āļąāļ‡āļ—āļĩāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļĢāļąāļāļĐāļēāđāļĨāđ‰āļ§" (The New England Journal of Medicine, 2020) āļšāļ—āļ„āļ§āļēāļĄāļ™āļĩāđ‰āļ™āļģāđ€āļŠāļ™āļ­āļœāļĨāļĨāļąāļžāļ˜āđŒāļ‚āļ­āļ‡āļāļēāļĢāļ—āļ”āļĨāļ­āļ‡āđāļšāļš 3 āđ€āļŸāļŠāļŠāļģāļŦāļĢāļąāļšāļžembroilizumab āļ‹āļķāđˆāļ‡āđ€āļ›āđ‡āļ™āļĒāļēāļ•āđ‰āļēāļ™āđ€āļ‹āļĨāļĨāđŒāļ—āļĩāđˆāļœāļīāļ”āļ›āļāļ•āļī āđ€āļ—āļĩāļĒāļšāļāļąāļšāđ„āļĄāđˆāļĄāļĩāļœāļĨāļŠāļģāļŦāļĢāļąāļšāļœāļđāđ‰āļ›āđˆāļ§āļĒāļĄāļ°āđ€āļĢāđ‡āļ‡āļœāļīāļ§āļŦāļ™āļąāļ‡āļ—āļĩāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļĢāļąāļāļĐāļēāđāļĨāđ‰āļ§
  1. "āļ„āļ§āļēāļĄāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļĢāļ°āļŦāļ§āđˆāļēāļ‡āļŠāļđāļ•āļĢāļ­āļēāļŦāļēāļĢāļāļąāļšāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āđ‚āļĢāļ„āļŦāļąāļ§āđƒāļˆ: āļāļēāļĢāļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļĢāļ°āļšāļšāļĢāļ°āđ€āļšāļĩāļĒāļšāđāļĨāļ°āļĢāļ§āļĄāļ‚āđ‰āļ­āļĄāļđāļĨ" (Circulation, 2022) āļšāļ—āļ„āļ§āļēāļĄāļ™āļĩāđ‰āļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļ„āļ§āļēāļĄāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļĢāļ°āļŦāļ§āđˆāļēāļ‡āļŠāļđāļ•āļĢāļ­āļēāļŦāļēāļĢāļāļąāļšāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āđ‚āļĢāļ„āļŦāļąāļ§āđƒāļˆ
  1. "āļ›āļĢāļ°āļŠāļīāļ—āļ˜āļīāļ āļēāļžāđāļĨāļ°āļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒāļ‚āļ­āļ‡āđ€āļĨāļ—āđ€āļ—āļ­āļĢāđŒāļĄāĨ‹āĪĩāļīāļĢāļŠāļģāļŦāļĢāļąāļšāļāļēāļĢāļ›āđ‰āļ­āļ‡āļāļąāļ™āļāļēāļĢāļ•āļīāļ”āđ€āļŠāļ·āđ‰āļ­ cytomegalovirus āđƒāļ™āļœāļđāđ‰āļĢāļąāļšāļ›āļĨāļđāļāļ–āđˆāļēāļĒāđ€āļ™āļ·āđ‰āļ­āđ€āļĒāļ·āđˆāļ­āđāļāļ”āļ­āđ‚āļĨāļāļĩ: āļāļēāļĢāļ—āļ”āļĨāļ­āļ‡āđāļšāļšāļŠāļļāđˆāļĄāļ—āļ§āļīāļ āļēāļ„āļ—āļĩāđˆāđ„āļĄāđˆāļ—āļĢāļēāļšāļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļ„āļ§āļšāļ„āļļāļĄāļ—āļĩāđˆāđ„āļĄāđˆāļ—āļĢāļēāļšāļŠāļąāļāļĨāļąāļāļĐāļ“āđŒ" (The Lancet Haematology, 2020) āļšāļ—āļ„āļ§āļēāļĄāļ™āļĩāđ‰āļāļĨāđˆāļēāļ§āļ–āļķāļ‡āļœāļĨāļĨāļąāļžāļ˜āđŒāļ‚āļ­āļ‡āļāļēāļĢāļ—āļ”āļĨāļ­āļ‡āđāļšāļš 3 āđ€āļŸāļŠāļŠāļģāļŦāļĢāļąāļšāļĒāļēāļ•āđ‰āļēāļ™āđ€āļŠāļ·āđ‰āļ­āđ€āļĨāļ—āđ€āļ—āļ­āļĢāđŒāļĄāļ­āļ§āļīāļĢāđƒāļ™āļāļēāļĢāļ›āđ‰āļ­āļ‡āļāļąāļ™āļāļēāļĢāļ•āļīāļ”āđ€āļŠāļ·āđ‰āļ­ cytomegalovirus āđƒāļ™āļœāļđāđ‰āļĢāļąāļšāļ›āļĨāļđāļāļ–āđˆāļēāļĒāđ€āļ™āļ·āđ‰āļ­āđ€āļĒāļ·āđˆāļ­āđāļāļ”āļ­āđ‚āļĨāļāļĩ
  1. "āļ›āļąāļˆāļˆāļąāļĒāđ€āļŠāļĩāđˆāļĒāļ‡āđāļĨāļ°āļœāļĨāļĨāļąāļžāļ˜āđŒāļ‚āļ­āļ‡āļ āļēāļ§āļ°āļ„āļąāļšāđ€āļ‰āļēāļ›āļĢāļ°āļŠāļēāļ—āļĢāļ°āļŦāļ§āđˆāļēāļ‡āļāļēāļĢāļœāđˆāļēāļ•āļąāļ”: āļāļēāļĢāļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļĢāļ°āļšāļšāļĢāļ°āđ€āļšāļĩāļĒāļšāđāļĨāļ°āļĢāļ§āļĄāļ‚āđ‰āļ­āļĄāļđāļĨ" (Anesthesiology, 2022) āļšāļ—āļ„āļ§āļēāļĄāļ™āļĩāđ‰āļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļ›āļąāļˆāļˆāļąāļĒāđ€āļŠāļĩāđˆāļĒāļ‡āđāļĨāļ°āļœāļĨāļĨāļąāļžāļ˜āđŒāļ‚āļ­āļ‡āļ āļēāļ§āļ°āļ„āļąāļšāđ€āļ‰āļēāļ›āļĢāļ°āļŠāļēāļ—āļĢāļ°āļŦāļ§āđˆāļēāļ‡āļāļēāļĢāļœāđˆāļēāļ•āļąāļ”
  1. "āļ›āļĢāļ°āļŠāļīāļ—āļ˜āļīāļ āļēāļžāđāļĨāļ°āļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒāļ‚āļ­āļ‡āļšāļēāđ€āļĄāļĨāļēāļ™āļīāđ€āļ§āļĄāļąāļšāđāļĨāļ°āđ€āļ­āđ€āļ—āļŠāļķāļ§āļīāļĄāļąāļšāđƒāļ™āļœāļđāđ‰āļ›āđˆāļ§āļĒāļ—
 
continue
output
  1. "āļ›āļĢāļ°āļŠāļīāļ—āļ˜āļīāļ āļēāļžāđāļĨāļ°āļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒāļ‚āļ­āļ‡āļšāļēāđ€āļĄāļĨāļēāļ™āļīāđ€āļ§āļĄāļąāļšāđāļĨāļ°āđ€āļ­āđ€āļ—āļŠāļķāļ§āļīāļĄāļąāļšāđƒāļ™āļœāļđāđ‰āļ›āđˆāļ§āļĒāļ—āļĩāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļĢāļąāļāļĐāļēāđƒāļ™āđ‚āļĢāļ‡āļžāļĒāļēāļšāļēāļĨāļ”āđ‰āļ§āļĒ COVID-19: āļāļēāļĢāļ—āļ”āļĨāļ­āļ‡āđāļšāļšāļŠāļļāđˆāļĄāļ—āļ§āļīāļ āļēāļ„āļ—āļĩāđˆāđ„āļĄāđˆāļ—āļĢāļēāļšāļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļ„āļ§āļšāļ„āļļāļĄāļ—āļĩāđˆāđ„āļĄāđˆāļ—āļĢāļēāļšāļŠāļąāļāļĨāļąāļāļĐāļ“āđŒ" (The New England Journal of Medicine, 2021) āļšāļ—āļ„āļ§āļēāļĄāļ™āļĩāđ‰āļ™āļģāđ€āļŠāļ™āļ­āļœāļĨāļĨāļąāļžāļ˜āđŒāļ‚āļ­āļ‡āļāļēāļĢāļ—āļ”āļĨāļ­āļ‡āđāļšāļš 3 āđ€āļŸāļŠāļŠāļģāļŦāļĢāļąāļšāļĒāļēāļ•āđ‰āļēāļ™āđ€āļŠāļ·āđ‰āļ­āļšāļēāđ€āļĄāļĨāļēāļ™āļīāđ€āļ§āļĄāļąāļšāđāļĨāļ°āđ€āļ­āđ€āļ—āļŠāļķāļ§āļīāļĄāļąāļšāđƒāļ™āļāļēāļĢāļĢāļąāļāļĐāļēāļœāļđāđ‰āļ›āđˆāļ§āļĒāļ—āļĩāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļĢāļąāļāļĐāļēāđƒāļ™āđ‚āļĢāļ‡āļžāļĒāļēāļšāļēāļĨāļ”āđ‰āļ§āļĒ COVID-19
  1. "āļ„āļ§āļēāļĄāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļĢāļ°āļŦāļ§āđˆāļēāļ‡āļ„āļļāļ“āļ āļēāļžāļ™āļ­āļ™āļāļąāļšāļŸāļąāļ‡āļāđŒāļŠāļąāđˆāļ™āļ›āļĢāļ°āļŠāļēāļ—āđƒāļ™āļœāļđāđ‰āļŠāļđāļ‡āļ­āļēāļĒāļļ: āļāļēāļĢāļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļĢāļ°āļšāļšāļĢāļ°āđ€āļšāļĩāļĒāļšāđāļĨāļ°āļĢāļ§āļĄāļ‚āđ‰āļ­āļĄāļđāļĨ" (Sleep, 2022) āļšāļ—āļ„āļ§āļēāļĄāļ™āļĩāđ‰āļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļ„āļ§āļēāļĄāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļĢāļ°āļŦāļ§āđˆāļēāļ‡āļ„āļļāļ“āļ āļēāļžāļ™āļ­āļ™āļāļąāļšāļŸāļąāļ‡āļāđŒāļŠāļąāđˆāļ™āļ›āļĢāļ°āļŠāļēāļ—āđƒāļ™āļœāļđāđ‰āļŠāļđāļ‡āļ­āļēāļĒāļļ
  1. "āļ›āļĢāļ°āļŠāļīāļ—āļ˜āļīāļ āļēāļžāđāļĨāļ°āļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒāļ‚āļ­āļ‡āļ—āļĢāļēāļŠāļ•āļđāļ‹āļđāļĄāļąāļšāđƒāļ™āļœāļđāđ‰āļ›āđˆāļ§āļĒāļĄāļ°āđ€āļĢāđ‡āļ‡āđ€āļ•āđ‰āļēāļ™āļĄāļ—āļĩāđˆāļĄāļĩ HER2-āļšāļ§āļ: āļāļēāļĢāļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļĢāļ°āļšāļšāļĢāļ°āđ€āļšāļĩāļĒāļšāđāļĨāļ°āļĢāļ§āļĄāļ‚āđ‰āļ­āļĄāļđāļĨ" (Breast Cancer Research and Treatment, 2022) āļšāļ—āļ„āļ§āļēāļĄāļ™āļĩāđ‰āļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļ›āļĢāļ°āļŠāļīāļ—āļ˜āļīāļ āļēāļžāđāļĨāļ°āļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒāļ‚āļ­āļ‡āļ—āļĢāļēāļŠāļ•āļđāļ‹āļđāļĄāļąāļšāđƒāļ™āļāļēāļĢāļĢāļąāļāļĐāļēāļœāļđāđ‰āļ›āđˆāļ§āļĒāļĄāļ°āđ€āļĢāđ‡āļ‡āđ€āļ•āđ‰āļēāļ™āļĄāļ—āļĩāđˆāļĄāļĩ HER2-āļšāļ§āļ
  1. "āļ›āļąāļˆāļˆāļąāļĒāđ€āļŠāļĩāđˆāļĒāļ‡āđāļĨāļ°āļœāļĨāļĨāļąāļžāļ˜āđŒāļ‚āļ­āļ‡āļ āļēāļ§āļ°āļĨāļīāđˆāļĄāđ€āļĨāļ·āļ­āļ”āđƒāļ™āļœāļđāđ‰āļ›āđˆāļ§āļĒāļ—āļĩāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļœāđˆāļēāļ•āļąāļ”: āļāļēāļĢāļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļĢāļ°āļšāļšāļĢāļ°āđ€āļšāļĩāļĒāļšāđāļĨāļ°āļĢāļ§āļĄāļ‚āđ‰āļ­āļĄāļđāļĨ" (Anesthesia & Analgesia, 2022) āļšāļ—āļ„āļ§āļēāļĄāļ™āļĩāđ‰āļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒāļ›āļąāļˆāļˆāļąāļĒāđ€āļŠāļĩāđˆāļĒāļ‡āđāļĨāļ°āļœāļĨāļĨāļąāļžāļ˜āđŒāļ‚āļ­āļ‡āļ āļēāļ§āļ°āļĨāļīāđˆāļĄāđ€āļĨāļ·āļ­āļ”āđƒāļ™āļœāļđāđ‰āļ›āđˆāļ§āļĒāļ—āļĩāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļœāđˆāļēāļ•āļąāļ” āđ‚āļ›āļĢāļ”āļ—āļĢāļēāļšāļ§āđˆāļēāļšāļ—āļ„āļ§āļēāļĄāđ€āļŦāļĨāđˆāļēāļ™āļĩāđ‰āđ€āļ›āđ‡āļ™āļšāļ—āļ„āļ§āļēāļĄāļ§āļīāļŠāļēāļāļēāļĢāļˆāļēāļāļ›āļĩ 2020 āđāļĨāļ° 2022 āđ‚āļ”āļĒāđ„āļĄāđˆāļĢāļ§āļĄāļšāļ—āļ„āļ§āļēāļĄāļˆāļēāļāļ›āļĩ 2024 āđ€āļ™āļ·āđˆāļ­āļ‡āļˆāļēāļāļ›āļĩ 2024 āļĒāļąāļ‡āđ„āļĄāđˆāļĄāļēāļ–āļķāļ‡
 
Built with Potion.so